Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Suppression of colorectal cancer by ketogenic diet and beta-hydroxybutyrate

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE196965 | GEO | 2022/02/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Suppression of colorectal cancer by ketogenic diet and beta-hydroxybutyrate

Project description:Suppression of colorectal cancer by ketogenic diet and beta-hydroxybutyrate

| PRJNA808081 | ENA

β-Hydroxybutyrate suppresses colorectal cancer.

Project description:Colorectal cancer (CRC) is among the most frequent forms of cancer, and new strategies for its prevention and therapy are urgently needed1. Here we identify a metabolite signalling pathway that provides actionable insights towards this goal. We perform a dietary screen in autochthonous animal models of CRC and find that ketogenic diets exhibit a strong tumour-inhibitory effect. These properties of ketogenic diets are recapitulated by the ketone body β-hydroxybutyrate (BHB), which reduces the proliferation of colonic crypt cells and potently suppresses intestinal tumour growth. We find that BHB acts through the surface receptor Hcar2 and induces the transcriptional regulator Hopx, thereby altering gene expression and inhibiting cell proliferation. Cancer organoid assays and single-cell RNA sequencing of biopsies from patients with CRC provide evidence that elevated BHB levels and active HOPX are associated with reduced intestinal epithelial proliferation in humans. This study thus identifies a BHB-triggered pathway regulating intestinal tumorigenesis and indicates that oral or systemic interventions with a single metabolite may complement current prevention and treatment strategies for CRC.

| S-EPMC9448510 | biostudies-literature

Influence of a ketogenic diet on glial metabolism in vivo

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-06-24 | GSE206577 | GEO

Embryonic response to high beta-hydroxybutyrate (BHB) levels in postpartum dairy cows

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-11-14 | GSE122646 | GEO

Ketogenic HMG-CoA lyase and its product β-hydroxybutyrate promote pancreatic cancer progression

Project description:Pancreatic ductal adenocarcinoma (PDA) tumor cells are deprived of oxygen and nutrients and therefore must adapt their metabolism to ensure proliferation. In some physiological states, cells rely on ketone bodies to satisfy their metabolic needs, especially during nutrient stress. Here, we show that PDA cells can activate ketone body metabolism, and that β-hydroxybutyrate (βOHB) is an alternative cell-intrinsic or systemic fuel that can promote PDA growth and progression. PDA cells activate enzymes required for ketogenesis, utilising various nutrients as carbon sources for ketone body formation. By assessing metabolic gene expression from spontaneously arising PDA tumors in mice, we find HMG-CoA lyase (HMGCL), involved in ketogenesis, to be among the most deregulated metabolic enzymes in PDA compared to normal pancreas. In-vitro depletion of HMGCL impedes migration, tumor cell invasiveness and anchorage-independent tumor sphere compaction. Moreover, disrupting HMGCL drastically decreases PDA tumor growth in vivo, while βOHB stimulates metastatic dissemination to the liver. These findings suggest that βOHB increases PDA aggressiveness and identify HMGCL and ketogenesis as metabolic targets for limiting PDA progression.

| S-SCDT-EMBOJ-2021-110466 | biostudies-other

Identification of miRNAs that regulate Colorectal Cancer Metastasis

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2015-01-15 | E-GEOD-56320 | biostudies-arrayexpress

Stromal contribution to expression signatures of colorectal cancer

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2014-05-01 | E-GEOD-56710 | biostudies-arrayexpress

A ketogenic diet can revert acquired resistance to immunotherapy in prostate cancer through β-hydroxybutyrate-mediated inhibition of histone deacetylases

Project description:Prostate cancer is the second leading cause of cancer deaths in men in the US. In the past decade, immune checkpoint blockade (ICB) drugs targeting programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) have revolutionized the field of cancer therapeutics, but the objective response rate in prostate cancers is in the low single digits. A major complicating issue is that immunotherapies can have significant adverse effects, so there is a clinical need for novel combinatorial strategies that do not involve additional or compounding adverse effects. We developed a model system of advanced prostate cancer that has acquired resistance to ICB therapy. The PD-1 resistant sublines showed strong downregulation of the mouse major histocompatibility complex (MHC-I), which was reversed by treating cells with either the pan-histone deacetylase (HDAC) inhibitor Vorinostat or β-hydroxybutyrate. When mice bearing these ICB resistant tumor are treated with either Vorinostat, with a cyclical ketogenic diet (CKD), or with a 1,3-butanediol diet (BD), tumors are resensitized to ICB therapy. We analyzed changes in the tumor immune microenvironment and showed that this effect is driven by a shift in monocyte differentiation, changing from M2 polarized immunosuppressive macrophages into iNOS+ dendritic cells instead. This differentiation is dependent on an ICB-induced increase in CD40L+ CD8+ T-cells in the tumor immune microenvironment. Our results indicate a novel mechanism in which a ketogenic diet can be used to increase therapeutic efficacy of ICB therapy.

2024-02-13 | GSE206561 | GEO

LGR5 positivity defines stem-like cells in colorectal cancer

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2013-05-07 | E-GEOD-46712 | biostudies-arrayexpress

Activation of AKT induces EZH2-mediated β-catenin trimethylation in colorectal cancer.

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-08-23 | GSE226589 | GEO